EF Hutton Initiates Coverage On GT Biopharma with Hold Rating, Announces Price Target of $2
EF Hutton analyst Tony Butler initiates coverage on GT Biopharma (NASDAQ:GTBP) with a Hold rating and announces Price Target of $2.
GT Biopharma, Inc. Announces $6.5M Registered Direct Offering Priced At Premium To Market
GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
GT Biopharma Q3 EPS $(0.22) Down From $(0.17) YoY
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.22) per share. This is a 29.41 percent decrease over losses of $(0.17) per share from the same period last year.
HC Wainwright & Co. Maintains Buy on GT Biopharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Robert Burns maintains GT Biopharma (NASDAQ:GTBP) with a Buy and lowers the price target from $25 to $5.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
SenesTech (NASDAQ:SNES) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
GT Biopharma, Inc. (the "Company" or "GTB") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer